(Q46955559)

26 December 2017

title

Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes (English)

1 reference

26 December 2017

0 references

1 reference

G Perriello

1

1 reference

26 December 2017

S Pampanelli

2

1 reference

26 December 2017

C Di Pietro

3

1 reference

26 December 2017

P Brunetti

4

1 reference

26 December 2017

Italian Pioglitazone Study Group

5

1 reference

26 December 2017

publication date

1 March 2006

1 reference

26 December 2017

published in

Diabetic Medicine

1 reference

26 December 2017

volume

23

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

246-252

1 reference

26 December 2017

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01801.X

10.1111/J.1464-5491.2006.01801.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

16492206

1 reference

26 December 2017